Chamber of Commerce asks judge to block Medicare drug price negotiations before October 1

Chamber of Commerce asks judge to block Medicare drug price negotiations before October 1


The U.S. Chamber of Commerce seal is displayed during restoration at the headquarters in Washington, D.C.

Andrew Harrer | Bloomberg | Getty Images

The U.S. Chamber of Commerce on Wednesday asked a federal judge in Ohio to block Medicare’s new powers to negotiate drug prices before October 1.

The motion for a preliminary injunction is a significant escalation in the pharmaceutical industry’s legal battle against Medicare that would halt the talks before they begin this fall.

Health and Human Services Secretary Xavier Becerra will publish a list of 10 high-cost drugs by September 1 that are selected for the negotiations. Drugmakers then have to decide whether to sign agreements to participate in the talks by October 1.

The U.S. Chamber and local chambers of commerce in Dayton, Ohio and Michigan sued Medicare in federal court in the southern district of Ohio in June. They argued that the drug negotiations violate the First and Fifth Amendments of the U.S. Constitution, as well as the separation of powers.

The Chamber asked Judge Thomas Rose on Wednesday to block the negotiations before they get underway because they violate the due process clause.

Drugmaker Abbvie, a member of the U.S. Chamber and the Dayton, Ohio area chamber, fears that its blood cancer drug Imbruvica will be selected for the negotiations this fall. Imbruvica generated $4.6 billion in revenue last year, or about 8% of the company’s total sales.

CNBC Health & Science

Read CNBC’s latest health coverage:

This is a developing story. Please check back for updates.



Source

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say
Health

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say

The growth of China’s biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That’s a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts […]

Read More
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Health

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]

Read More
OpenAI acquires health-care technology startup Torch
Health

OpenAI acquires health-care technology startup Torch

OpenAI has acquired the health-care technology startup Torch, the company announced on Monday. Torch was building a “unified medical memory” for artificial intelligence that aimed to bring a patient’s health data, which is typically siloed and stored across a number of different vendors and formats, into one place. Torch’s employees will join OpenAI as part […]

Read More